KORU Medical Q3 Revenue Jumps 11% to $11.6M, Net Income Positive

KORU Medical Systems (NASDAQ: KRMD) reported third-quarter 2026 net revenues of $11.6 million on 10 November 2026, up 11.2% from $10.4 million a year earlier, while swinging to net income of $0.2 million from a $0.8 million loss. Adjusted EBITDA rose to $1.3 million from $0.1 million. The company also trimmed the top of its full-year revenue guidance to $48.0-$48.5 million, narrowing from a prior $47.5-$48.5 million range.

Context — why KORU Medical's Q3 2026 results matter now

The quarter marks KORU's second consecutive period of positive net income and positive adjusted EBITDA, a shift the company frames as evidence its cost structure can scale. A year ago the same quarter produced a $0.8 million net loss and just $0.1 million in adjusted EBITDA, so the swing is roughly $1.0 million on both lines.

The comparison base is unusually noisy, and the company said so directly. Domestic core revenue jumped 31.6% to $8.1 million, but KORU attributed roughly $1.2 million of that gain to a U.S. distributor that had bought through an international distributor in the third quarter of 2025 and drew down inventory. That single ordering quirk distorts both the domestic and international lines.

International core revenue fell 16.5% to $3.1 million, which the company tied to a prior-year period that included shipments to a distributor in a strategic market ahead of vial-to-prefilled conversions, plus purchases by an international distributor for resale back into the U.S.

Management also flagged the timing of its entry into a competitive non-tender market in Europe as a drag on the year-over-year growth rate, which moderated from the first half. CEO Adam Kalbermatten said the launch is now behind the company and expects growth to reaccelerate in the fourth quarter.

Gross margin is the cleaner signal. It expanded to 65.2% from 60.2%, which KORU credited to lower manufacturing costs, a favorable geographic customer mix lifting average selling prices, and lower tariff costs from tariff-related rebates.

Data — what the numbers show

Revenue growth came almost entirely from the core business, which rose 13.5% to $11.1 million and represented 96.3% of net revenues versus 94.4% a year earlier. Pharma services and clinical trials fell 27.4% to $0.4 million, which the company attributed to lower purchases for a customer's clinical trial program.

Metric	Q3 2026	Q3 2025	Change
Net revenues	$11.57M	$10.40M	+11.2%
Gross profit	$7.55M	$6.26M	+20.5%
Gross margin	65.2%	60.2%	+500 bps
Net income/(loss)	$0.22M	($0.78M)	+$1.0M
Adjusted EBITDA	$1.31M	$0.09M	+$1.2M

Operating expenses rose 3.2% to $7.4 million, driven by a $0.3 million increase in research and development tied to salary and stock compensation from headcount additions, including employees added through a technology asset acquisition. Selling, general and administrative costs actually fell to $5.9 million from $6.0 million.

Cash and cash equivalents stood at $7.4 million on 30 September 2026, down $0.9 million in the quarter and $1.5 million over the nine months. Inventory rose to $4.7 million from $3.7 million at year-end 2025. The company raised its year-end cash target to greater than $8.0 million from greater than $7.5 million.

Year to date, net revenues reached $35.4 million, up 17% from $30.2 million, while the company still carried a $0.3 million net loss and a $0.01 diluted loss per share for the nine months.

Analysis — what it means for markets and the medtech sector

KORU's improving margin profile matters more than the headline revenue number, because the company's recurring consumable and pump base is what management points to as the engine of above-market growth. A 500 basis point margin gain on roughly flat operating expense growth is the arithmetic behind the net income swing, and it is the kind of operating use that small-cap medtech names are typically valued on.

The limitation is that the top line is not clean. Excluding the distributor ordering distortion, domestic growth would look materially smaller, and the international decline is partly a comparison artifact rather than a demand signal. Investors cannot fully separate underlying patient growth from distributor inventory timing using the disclosed figures alone.

The guidance change cuts both ways. KORU narrowed the range rather than raising it outright, lifting the floor by $0.5 million but lowering the ceiling by the same amount. That is a modest tightening, not an upgrade, and it sits alongside a raised gross margin range of 63-64% from 62-64%.

Second-order effects land on the subcutaneous infusion niche and on the specialty pharmacy partnerships KORU cited as a growth channel. Distributor-led medtech names with concentrated U.S. channels carry inventory-timing risk that shows up as quarterly noise, which is exactly what this report demonstrates.

Positioning is likely to hinge on whether the fourth quarter delivers the reacceleration management promised, since the company tied its own outlook to that assumption.

Outlook — what to watch next

KORU reiterated positive adjusted EBITDA for the full year and now guides to a year-end cash balance above $8.0 million. The company did not disclose the terms of the two new sales and distribution agreements signed with partners in Europe and Africa, so their revenue contribution is not quantifiable from this report.

The near-term catalyst is the fourth-quarter revenue print, which will test the company's stated expectation that growth reaccelerates after the European non-tender market launch. Full-year revenue guidance of $48.0-$48.5 million implies 17-18% growth.

Gross margin is the second checkpoint. Hitting the raised 63-64% full-year range requires the fourth quarter to hold near the 65.2% level reported for Q3, given the year-to-date margin implied by nine-month gross profit of $22.6 million on $35.4 million of revenue.

Investors should also track cash. The company used $0.9 million in the third quarter and needs to reverse that trend to reach its raised year-end target.

Frequently Asked Questions

Why did KORU Medical's international revenue fall 16.5%?

The company said the decline mainly reflected a higher prior-year comparison base. That base included shipments to a distributor in a strategic market ahead of expected vial-to-prefilled conversions, plus purchases by an international distributor for resale in the U.S. Growth in new patient starts within existing international markets partially offset the drop.

Is KORU Medical profitable now?

On a quarterly basis, yes. KORU reported net income of $0.2 million for the third quarter of 2026 and adjusted EBITDA of $1.3 million, its second consecutive quarter of positive results on both measures. For the nine months ended 30 September 2026, however, the company still reported a net loss of $0.3 million, or $0.01 per diluted share.

What is KORU Medical's full-year 2026 revenue guidance?

KORU revised full-year 2026 revenue guidance to $48.0-$48.5 million, representing year-over-year growth of 17-18%, compared with its previous range of $47.5-$48.5 million. The company also raised its full-year gross margin range to 63-64% from 62-64%, reiterated positive adjusted EBITDA, and lifted its year-end cash target to greater than $8.0 million.

Bottom Line

KORU's margin-driven swing to profit is real, but the fourth quarter must prove the growth reacceleration management promised.

Disclaimer: This article is for informational purposes only and does not constitute investment advice. CFD trading carries high risk of capital loss.